Add BrightSurf on Google Email

Study shows why immune-boosting therapy doesn't work for everyone with widespread melanoma

A recent study published at ASCO found that gene dysregulation causes immune T cells to turn back to an immature state, making them less effective against metastatic melanoma. The researchers discovered over 60 epigenetic changes and 10 changes in gene activity that were most common among patients who didn't respond to immunotherapy.

NIH-funded study suggests potential to predict peanut allergy immunotherapy outcomes

A new NIH-funded study suggests that changes in immune cell subtypes after oral immunotherapy for peanut allergy can help predict treatment success. The research, published in Proceedings of the National Academy of Sciences, found a novel T-cell population that likely would not mount an allergic response expanded with treatment.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalProceedings of the National Academy of Sciences·DateJan 25, 2016

Subcutaneous administration of multispecific antibody improves tumor treatment

Researchers found that subcutaneous administration of multispecific antibodies improves tumor treatment by better tolerability and undiminished effectiveness. The study suggests that this method could lead to broader availability of tumor treatment for patients, potentially eliminating hospitalization.

NIH-funded researchers identify new genetic immune disorder

Researchers have identified a new genetic immune disorder, DOCK2 deficiency, which causes debilitating infections and combined immunodeficiency in children. Early screening for the disease can prevent life-threatening infections, and understanding its role may inform the study of more common immune system disorders.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNew England Journal of Medicine·DateJun 17, 2015

Identification of drug combinations that reverse HIV-1 latency

Researchers have developed a multifaceted approach to identify drug combinations that reverse HIV-1 latency. Several 2-drug combinations were found to be able to reactivate HIV-1 without triggering an inflammatory response, and a model was created to correlate changes in viral RNA with virus secretion from T cells.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMar 30, 2015